Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JK-1201I versus topotecan in relapsed extensive-stage small cell lung cancer
ChiCTR2400090371Phase 3Not yet recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of JK-1201I and topotecan in small cell lung cancer (SCLC) (2 arms), sponsored by Jilin Provincial Cancer Hospital. Primary endpoint: Overall survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
JK-1201Itopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400090371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090371.